^
    22d
    Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial. (PubMed, Nat Med)
    These findings suggest that iSBRT + anti-PD-L1 may convert immune-cold ER+HER2- BC into more inflamed tumors and improve response, particularly in PD-L1-negative disease. ClinicalTrials.gov registration: NCT03875573 .
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    PD-L1 expression • ER positive • HER-2 negative • PD-L1 negative • HER-2 negative + ER positive
    |
    MammaPrint®
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    25d
    DOSa: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    29d
    PACIFIC-9: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1051, Active, not recruiting, AstraZeneca | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    1m
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Dec 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    2ms
    Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. (PubMed, Clin Cancer Res)
    These findings support the clinical activity and tolerability of durvalumab plus paclitaxel in locally advanced unresectable/mTNBC, as expected for an immune checkpoint inhibitor in combination with chemotherapy. Addition of capivasertib or oleclumab to this treatment combination showed no substantial additional benefit. PD-L1 expression was associated with enhanced antitumor activity across all arms.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • paclitaxel • Truqap (capivasertib) • oleclumab (MEDI9447)
    2ms
    A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2027 --> Mar 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    2ms
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    7ms
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Feb 2028 --> Aug 2028 | Initiation date: Sep 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Oct 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    7ms
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    9ms
    Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oleclumab (MEDI9447)
    10ms
    Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Sep 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    11ms
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)